The REMEDIES (RE-configuring MEDIcines End-to-end Supply) project, launched in 2014, is headed up by GlaxoSmithKline (GSK) with research led by the University of Cambridge’s Institute for Manufacturing. It brings together key players in the end-to-end supply chain, including major contract manufacturing organisations, equipment manufacturers along with regulators, knowledge transfer networks and healthcare providers (see the full list of partners here).
The UK’s pharmaceutical sector makes a major contribution to the UK economy: in 2013 the manufacture of pharmaceutical products accounted for 9% of UK’s manufacturing economy (read more here). However, there remain significant opportunities to address supply
chain inefficiencies which add costs and reduce productivity. At the same time, new technologies are emerging which have the potential to improve medicine
manufacturing and supply, and offer more personalised, faster and cheaper drug delivery. To provide a better service to
patients and to safeguard jobs across the UK, the sector needs to find innovative ways to tackle inefficiencies and capitalise on these new opportunities.
The project, due to be completed in March 2018 has several technology based application projects underpinned by two platform projects: clinical trials supply chains, led by GSK, and commercial supply chains led by IfM. The project involves several inter-related application workstreams – for further details on project structure click here.
Press Release – August 2015